PubMed Health⌕ Search

PubMed · 7660836

Structure activity relationship in toxicology.

Abstract

One of the basic principles of the modern pharmacological research is that there is a close correlation between the chemical structure and the pharmacological effect. In contrast to pharmacology, in toxicology high doses of the drugs are used in order to provoke toxic symptoms generally realized through other receptors than the pharmacological effect. The evaluation of the structure activity relationship (SAR) in toxicology is hindered by the fact that it is not possible to establish in every case that the toxic effect 1. is developed by the original compound or its metabolite(s) 2. is realized through one or more receptors. Furthermore it is necessary to take into consideration that the studies in toxicology are not carried out with so many compounds as the studies in pharmacology and--horrible dictu--the toxicological data are not always public. Thus the prediction of the toxicity of a compound on the base of its chemical structure is difficult, and the prediction whether a new drug is toxic to such an extent that excludes its development, is impossible. What we can do is trying to predict--in the knowledge of the metabolism of the drug--its possible carcinogenic, hepatotoxic, CNS etc. toxic effect.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L Vereczkey. 1995. Structure activity relationship in toxicology.. https://pubmed.ncbi.nlm.nih.gov/7660836/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗